Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 32Recruiting 16Terminated 9Unknown 3Enrolling by invitation 3Withdrawn 2Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Dermatologic 244Thoracic 69Genitourinary 54Gastrointestinal 51Head & Neck 47Gynecologic 31Breast 30Sarcoma 28CNS 20Other solid neoplasm 10Lymphoid 10Plasma cell 2Other hematologic neoplasm 2Myeloid 2Endocrine 2NET 1

Conditions

Leukemia, Myeloid, Acute 212Leukemia, Lymphocytic, Chronic, B-Cell 137Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Hematologic Neoplasms 117Myelodysplastic Syndromes 98Leukemia 84Lymphoma 69Lymphoma, Non-Hodgkin 59Multiple Myeloma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Leukemia, Myelomonocytic, Chronic 36Neoplasms 31Myeloproliferative Disorders 28Recurrence 25Burkitt Lymphoma 25Lymphoma, Mantle-Cell 23Leukemia, Biphenotypic, Acute 23Lymphoma, Large B-Cell, Diffuse 22Lymphoma, Follicular 20Lymphoma, B-Cell, Marginal Zone 20Lymphoma, B-Cell 20Leukemia, Myeloid, Chronic-Phase 16Leukemia, B-Cell 16Hodgkin Disease 16Primary Myelofibrosis 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Waldenstrom Macroglobulinemia 14Hematologic Diseases 14Anemia, Refractory, with Excess of Blasts 13Leukemia, Myeloid, Accelerated Phase 10

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Paracentesis 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Melanoma × Other hematologic neoplasm × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04314401 2026-05-13

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

Active not recruiting
1,600 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡